The anti-rejection drug sirolimus may protect kidney transplant patients from graft rejection over the long term even when the patients have not taken their anti-rejection medications regularly, a Division of Nephrology research team has found.
The team is headed by Robert Steiner, M.D., Professor of Medicine and Director of Transplant Nephrology, and includes Nitin Khosla, M.D., and Rodolfo Batarse, M.D., Assistant Professor of Medicine.First author Cheri Ye, M.D., presented the results at the 2008 American Transplant Congress in Toronto on May 31:

Ye X, Khosla N, Batarse R, Perkins D, Steiner R: Sirolimus (SRL) Blunts Mitogen Response at Trough (C0) Levels More Than Cyclosporin (CSA) or Tacrolimus (TAC) — A Safeguard for Our Many Long Term Noncompliant Kidney Transplant Patients (KTP’s)?

Read the full story
from UC San Diego
Health Sciences Communications

More Information

%d bloggers like this: